FY2025 · ended Dec 31, 2025 · Revenue $8.99M · Filed Mar 24, 2026
Bioage Labs, Inc. (BIOA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $9.0 million and a net loss of $80.6 million. Free cash flow was -$82.3 million. As of Jun 30, 2026 it held $381.2 million in cash and investments and $2.8 million in total debt.
Revenue (TTM)
$10.36M
Net income (TTM)
$-94.46M
Operating cash flow (TTM)
$-87.60M
Free cash flow (TTM)
$-88.09M
EPS (TTM)
$-2.37
Dividend per share
None
Shares outstanding
44.38M
+23.8% vs prior year
Net cash
$378.41M
as of Jun 30, 2026
Operating margin
-1026.3%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BIOA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1709941
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | $9.0M | — |
| Operating income | -$92.8M | -$78.2M |
| Net income | -$80.6M | -$71.1M |
| Diluted EPS | -$2.24 | -$6.63 |
| Operating cash flow | -$81.6M | -$51.5M |
| Free cash flow | -$82.3M | -$51.9M |
| Total assets | $294.9M | $358.2M |
| Total liabilities | $22.8M | $35.1M |
| Stockholders' equity | $272.1M | $323.1M |
| Cash and investments | $285.1M | $354.4M |
| Total debt | $5.6M | $8.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 2, 2026 | Oct 2, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Results of operations
|
May 8, 2026 | May 8, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
All 155 Bioage Labs, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.